Rajni Sinha

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 734 citations · Full text

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Journal of Clinical Oncology · 2013 · 348 citations · Full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 313 citations · Full text

Breast Oncology, Medicine, Clinical Trials +7

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Wei-Gang Tong, Rong Chen, William Plunkett et al. · Journal of Clinical Oncology · 2010 · 215 citations

Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United States

Pareen J. Shenoy, Neha Malik, Ajay K. Nooka et al. · Cancer · 2010 · 153 citations · Full text